Stockreport

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

Evommune, Inc.  (EVMN) 
PDF - Trial met primary efficacy endpoint at week 12- EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo- 33% placebo-adjus [Read more]